# Accent Microcell Limited

March 25, 2026

| Facilities/Instruments | Amount (₹ crore) | Rating[1] | Rating Action |
|---|---|---|---|
| Long-term bank facilities | 1.48<br>(Reduced from 1.66) | CARE A-; Stable | Upgraded from CARE BBB+; Stable |
| Long-term / Short-term bank facilities | 35.00<br>(Enhanced from 20.50) | CARE A-; Stable / CARE A2+ | Upgraded from CARE BBB+; Stable / CARE A2 |
| Short-term bank facilities | 5.50<br>(Enhanced from 3.77) | CARE A2+ | Upgraded from CARE A2 |
| Long-term / Short-term bank facilities | - | - | Withdrawn |
| Short-term bank facilities | - | - | Withdrawn |

Details of instruments/facilities in Annexure-1.

## Rationale and key rating drivers

The upward revision in ratings assigned to bank facilities of Accent Microcell Limited (AML) factors in significant growth in its scale of operations in FY25 (Audited, April 01 to March 31) and H1FY26 (Unaudited) while maintaining its healthy profitability due to its presence in a niche segment of pharmaceutical excipient industry. AML raised equity via rights issue in June 2025 for its capex requirement resulting in augmentation of net worth base to over ₹250 crore as on September 30, 2025.

Ratings continue to derive strength from the promoters' extensive experience, certified manufacturing facilities, moderately diversified customer base, healthy profitability, comfortable financial risk profile, and adequate liquidity.

However, ratings remain constrained by AML's moderate scale of operations, susceptibility to raw material price volatility and foreign exchange rates, and its presence in a highly competitive pharmaceutical industry.

The long-term / short-term bank facilities and short-term bank facilities have been withdrawn due to reclassification of some of bank facilities in line with the latest bank sanction letter.

## Rating sensitivities: Factors likely to lead to rating actions

**Positive factors**

- Significant volume-backed growth in scale of operations with total operating income (TOI) to over ₹500 crore while maintaining healthy profit before interest, lease rentals, depreciation and taxation (PBILDT) margin and comfortable financial risk profile.

**Negative factors**

- Decline in scale of operations with TOI below ₹250 crore and decline in profitability on sustained basis.
- Deterioration in overall gearing to over 0.50x.
- Any significant elongation in operating cycle impacting the liquidity of the company.

**Analytical approach:** Standalone

**Outlook:** Stable

Stable outlook reflects CARE Ratings Limited's (CareEdge Rating's) expectation that AML shall continue to benefit from its experienced promoters and niche product segment which shall enable it to sustain its healthy profitability and comfortable strong financial risk profile.

## Detailed description of key rating drivers:

### Key strengths

**Significant growth in scale of operations and healthy profitability**

AML manufactures Micro Crystalline Cellulose (MCC) and other excipient powders, such as Croscarmellose Sodium (CCS) and Magnesium Stearate (CMS), which find application in pharmaceutical industry as a bulking agent, binding and coating agent

[1]Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited's publications.

among others, while it is also used in food industry, nutraceutical industry, cosmetics, and others, as a fat substitute, filler, disintegrant, and flow aid among others. The company operates two manufacturing facilities at Pirana and Dahej, Gujarat, which are ISO 9001:2015, FSSC 22000, Good Manufacturing Practice (GMP), and Hazard Analysis and Critical Control Points (HACCP) certified. The Pirana plant was established in 2012, while the Dahej plant was set up as a Special Economic Zone (SEZ) unit in FY15, providing tax-related benefits. Its key products are also United States Drug Master File (US-DMF), Kosher, and Halal certified.

The TOI of AML grew by 11% year-on-year (y-o-y) to ₹273.86 crore in FY25 on the back of improved sales realisation. In H1FY26 as well, AML continued to report healthy growth with TOI of ₹139.37 crore compared to ₹126.04 crore in H1FY25, supported by 11% y-o-y volume growth and increase in sales realisation. Due to presence in niche segment, AML reported healthy PBILDT margin of 16% in FY25, which further improved to 17.83% in H1FY26.

CareEdge Ratings expects AML to achieve TOI of over ₹300 crore in FY26 while maintaining its prevailing healthy PBILDT margin.

**Comfortable financial risk profile**

With low reliance on debt on the back of healthy cash accrual generation, AML reported a strong capital structure with overall gearing of 0.01x as on March 31, 2025 (0.08x as at FY24-end) and September 30, 2025. AML's net worth base strengthened to ₹252.62 crore as on September 30, 2025, following equity infusion through a Rights Issue in June 2025. The proceeds were mainly raised for its capex requirement.

AML is undertaking a capacity expansion of 12,000 metric tonnes per annum (MTPA) for MCC at an estimated cost of ₹60 crore, which is expected to be completed by November 2026. The capex shall be funded by funds raised through rights issue and internal accruals.

Apart from this capex, AML is setting up a new manufacturing unit at Kheda, Gujarat, which will manufacture CCS, Sodium Starch Glycolate, and CMC. The project shall be entirely funded through the money raised through initial public offering (IPO) in December 2023. The project was earlier expected to commence commercial operations from October 2025; however, due to delay in receipt of regulatory approvals, the project was delayed and is now expected to commence commercial operations from April, 2026. With no debt planned to be availed for these projects, the capital structure is expected to remain comfortable over the medium term.

With reduced debt reliance and healthy profitability, debt coverage indicators strengthened in FY25, with PBILDT interest coverage of 129x and total debt to gross cash accruals (TD/GCA) of 0.04x in FY25 (37x and 0.36x, respectively, in FY24). In H1FY26 as well, AML reported PBILDT interest coverage of 64x and TD/GCA of 0.03x.

**Moderately diversified clientele with established marketing network**

AML caters to pharmaceutical, nutraceutical, and cosmetic industries and exports to the United States, Australia, the United Kingdom, and Russia. Exports contributed ~51% of TOI in FY25 (59% in FY24), mitigating geographical concentration risk to an extent. Customer concentration remained moderate, with the top 10 customers contributing 44.10% of TOI in FY25 (39% in FY24).

**Experienced promoters**

AML was established in 2002 and was converted into a closely held public limited company in December 2022, followed by listing on the NSE SME platform in December 2023. The key promoters, Ghanshyam Patel, Nitin Patel, Vasant Patel, and Vinod Patel, have ~20 years of experience in manufacturing MCC and other cellulose powders.

## Key weaknesses

**Susceptibility of profitability to raw material price and foreign exchange rate fluctuation**

The main raw material required by the company is wood pulp and therefore changes in wood pulp prices may adversely affect the company's profit margin. The company's ability to pass on the increase in raw material prices to its customers remains crucial. The company imports part of its raw material requirement and exports its final product. Therefore, AML is exposed to the fluctuation in foreign exchange rate for unhedged portion in absence of active hedging policy.

**Presence in highly competitive pharmaceutical industry**
MCC market is fragmented owing to presence of large number of manufacturers, which includes both organised and unorganised players. However, AML has large manufacturing facility, established marketing network, and long relationship with its customers; hence, the said risk is mitigated to a certain extent.

**Liquidity**: Adequate
Liquidity of AML is adequate, supported by positive cash flow from operations and low utilisation of working capital limits. Against GCA of ₹35.16 crore in FY25, AML had annual debt repayment obligation of less than ₹0.70 crore over the next three years, indicating comfortable debt servicing ability. Utilisation of working capital limits remained low at 10.42% in the past 12 months ending January 2026, reflecting efficient working capital management. AML's operating cycle remained moderate at 104 days in FY25 compared to 88 days in FY24, with the elongation primarily attributable to higher collection period due to high year-end sales.

**Assumptions/Covenants**: Not applicable

**Environment, social, and governance (ESG) risks**: Not applicable

## Applicable criteria

Definition of Default
Liquidity Analysis of Non-financial sector entities
Rating Outlook and Rating Watch
Manufacturing Companies
Financial Ratios – Non financial Sector
Withdrawal Policy
Short Term Instruments

## About the company and industry

### Industry classification

| Macroeconomic indicator | Sector | Industry | Basic industry |
|---|---|---|---|
| Commodities | Chemicals | Chemicals and petrochemicals | Commodity chemicals |

Ahmedabad-based (Gujarat) AML is promoted by Ghanshyam Patel, Vasant Patel, Vinod Patel, and Nitin Patel. The company was established as partnership firm in 2002 in the name of 'Accent Microcell Industries' and subsequently got converted into private limited company in April 2012 by the name of Accent Microcell Private Limited. Later, in December 2022, the company got converted into closely held public limited company. On December 15, 2023, AML raised ₹78.40 crore via initial public offering and got listed on NSE SME platform. The company is engaged in manufacturing MCC and other excipient powders, such as CCS and MS. The products manufactured by AML are largely used in pharmaceutical industry as a bulking agent, binding and coating agent among others, while it is also used in food industry, nutraceutical industry, cosmetics industry as a fat substitute, filler, disintegrant, flow aid among other applications. Its manufacturing facilities at Pirana and Dahej in Gujarat have a combined installed capacity of 9200 metric tonnes per annum (MTPA) and the same are ISO 9001:2015, FSSC 22000, GMP and HACCP certified. Its key products also hold US-DMF, Kosher, and Halal certifications.

| Brief Financials (₹ crore) | March 31, 2024 (A) | March 31, 2025 (A) | H1FY26 (UA) |
|---|---|---|---|
| Total operating income | 247.14 | 273.86 | 139.37 |
| PBILDT* | 41.21 | 43.82 | 23.91 |
| Profit after tax (PAT) | 30.17 | 33.06 | 18.07 |
| Overall gearing (x) | 0.08 | 0.01 | 0.00 |
| Interest coverage (x) | 36.73 | 129.08 | 64.07 |

A: Audited UA: Unaudited; Note: these are latest available financial results
*PBILDT: Profit before interest, lease rentals, depreciation, and tax

**Status of non-cooperation with previous CRA:** CRISIL has continued the rating assigned to bank facilities of AML into ISSUER NOT COOPERATING category vide press release dated February 27, 2026, considering its inability to carry out a review in the absence of requisite information from the company.

**Any other information:** Not applicable

**Rating history for last three years:** Annexure-2

**Detailed explanation of covenants of rated instrument / facility:** Annexure-3

**Complexity level of instruments rated**: Annexure-4

**Lender details**: Annexure-5

### Annexure-1: Details of instruments/facilities

| Name of the Instrument | ISIN | Date of Issuance (DD-MM-YYYY) | Coupon Rate (%) | Maturity Date (DD-MM-YYYY) | Size of the Issue (₹ crore) | Rating Assigned and Rating Outlook |
|---|---|---|---|---|---|---|
| Fund-based - LT-Term Loan | - | - | - | 20/11/2027 | 1.48 | CARE A-; Stable |
| Fund-based - ST-Bill Discounting/ Bills Purchasing | - | - | - | - | 2.00 | CARE A2+ |
| Fund-based - ST-Forward Contract | - | - | - | - | 3.50 | CARE A2+ |
| LT/ST Fund-based/Non-fund-based-EPC / PCFC / FBP / FBD / WCDL / OD / BG / SBLC | - | - | - | - | 35.00 | CARE A-; Stable / CARE A2+ |
| Non-fund-based - LT/ ST-Bank Guarantee | - | - | - | - | 0.00 | Withdrawn |
| Non-fund-based - ST-Letter of credit | - | - | - | - | 0.00 | Withdrawn |

### Annexure-2: Rating history for last three years

| Sr. No. | Name of the Instrument/Bank Facilities | Current Ratings | | | Rating History | | | |
|---|---|---|---|---|---|---|---|---|
| | | Type | Amount Outstanding (₹ crore) | Rating | Date(s) and Rating(s) assigned in 2025-2026 | Date(s) and Rating(s) assigned in 2024-2025 | Date(s) and Rating(s) assigned in 2023-2024 | Date(s) and Rating(s) assigned in 2022-2023 |
| 1 | LT/ST Fund-based/Non-fund-based-EPC / PCFC / FBP / FBD / WCDL / OD / BG / SBLC | LT/ST | 35.00 | CARE A-; Stable / CARE A2+ | - | 1)CARE BBB+; Stable / CARE A2 (20-Mar-25) | 1)CARE BBB+; Stable / CARE A2 (26-Mar-24)<br><br>2)CARE BBB; Stable / CARE A3+ (03-Apr-23) | - |
| 2 | Non-fund-based - ST-Letter of credit | ST | - | - | - | 1)CARE A2 (20-Mar-25) | 1)CARE A2 (26-Mar-24)<br><br>2)CARE A3+ (03-Apr-23) | - |
| 3 | Non-fund-based - LT/ ST-Bank Guarantee | LT/ST | - | - | - | 1)CARE BBB+; Stable / CARE A2 (20-Mar-25) | 1)CARE BBB+; Stable / CARE A2 (26-Mar-24)<br><br>2)CARE BBB; Stable / CARE A3+ (03-Apr-23) | - |
| 4 | Fund-based - LT-Term Loan | LT | 1.48 | CARE A-; Stable | - | 1)CARE BBB+; Stable (20-Mar-25) | 1)CARE BBB+; Stable (26-Mar-24)<br><br>2)CARE BBB; Stable (03-Apr-23) | - |
| 5 | Fund-based - ST-Bill Discounting/ Bills Purchasing | ST | 2.00 | CARE A2+ | - | 1)CARE A2 (20-Mar-25) | 1)CARE A2 (26-Mar-24)<br><br>2)CARE A3+ (03-Apr-23) | - |
| 6 | Fund-based - ST-Forward Contract | ST | 3.50 | CARE A2+ | - | 1)CARE A2 (20-Mar-25) | 1)CARE A2 (26-Mar-24)<br><br>2)CARE A3+ (03-Apr-23) | - |

LT: Long term; ST: Short term; LT/ST: Long term/Short term

**Annexure-3: Detailed explanation of covenants of rated instruments/facilities:** Not applicable

### Annexure-4: Complexity level of instruments rated

| Sr. No. | Name of the Instrument | Complexity Level |
|---|---|---|
| 1 | Fund-based - LT-Term Loan | Simple |
| 2 | Fund-based - ST-Bill Discounting/ Bills Purchasing | Simple |
| 3 | Fund-based - ST-Forward Contract | Simple |
| 4 | LT/ST Fund-based/Non-fund-based-EPC / PCFC / FBP / FBD / WCDL / OD / BG / SBLC | Simple |
| 5 | Non-fund-based - LT/ ST-Bank Guarantee | Simple |
| 6 | Non-fund-based - ST-Letter of credit | Simple |

### Annexure-5: Lender details

| |
|---|
| To view lender-wise details of bank facilities please click here |

**Note on complexity levels of rated instruments:** CareEdge Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

**Contact us**

| Media Contact | Analytical Contacts |
|---|---|
| Mradul Mishra<br>Director<br>**CARE Ratings Limited**<br>Phone: +91-22-6754 3596<br>E-mail: mradul.mishra@careedge.in<br><br>**Relationship Contact**<br><br>Ankur Sachdeva<br>Senior Director<br>**CARE Ratings Limited**<br>Phone: +91-22-6754 3444<br>E-mail: Ankur.sachdeva@careedge.in | Kalpesh Ramanbhai Patel<br>Director<br>**CARE Ratings Limited**<br>Phone: 079-40265611<br>E-mail: kalpesh.patel@careedge.in<br><br>Anuja Parikh<br>Associate Director<br>**CARE Ratings Limited**<br>Phone: +079-4026 5616<br>E-mail: anuja.parikh@careedge.in<br><br>Sarvesh Harish Gaikar<br>Rating Analyst<br>**CARE Ratings Limited**<br>E-mail: Sarvesh.gaikar@careedge.in |

**About us:**

Established in 1993, CareEdge Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the Reserve Bank of India. With an equitable position in the Indian capital market, CareEdge Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CareEdge Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CareEdge Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit. For more information: www.careratings.com



**For detailed Rating Report and subscription information,**
**please visit www.careratings.com**